Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alexander Hardy
Pharma
BioMarin pulls gene therapy Roctavian off the market
The company resigned to withdrawing its hemophilia A gene therapy from the market after failing to find the med a buyer.
Zoey Becker
Feb 24, 2026 12:30pm
BioMarin unveils strategic redesign under CEO Alexander Hardy
Sep 4, 2024 5:32pm
BioMarin lays off 225 more staffers under new corporate strategy
Aug 29, 2024 4:30am
With slow sales, BioMarin weighs Roctavian divestiture
Apr 29, 2024 11:51am
BioMarin's hemophilia gene therapy needs 3 stars to align: CEO
Feb 23, 2024 10:15am
JPM24: New BioMarin CEO Hardy makes his priorities clear
Jan 10, 2024 11:29am
